NASDAQ:PCRX - Pacira BioSciences Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $82.00
Forecasted Upside: 33.53 %
Number of Analysts: 7
Breakdown:
0 Sell Ratings
2 Hold Ratings
5 Buy Ratings
0 Strong Buy Ratings

^$61.41 As of 05/18/2022 05:00 PM ET

▼ -2.17 (-3.41%)

1 month | 3 months | 12 months

Get New Pacira BioSciences Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for PCRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PCRX

^$82.00

▲ +33.53% Upside Potential

This price target is based on 7 analysts offering 12 month price targets for Pacira BioSciences in the last 3 months. The average price target is $82.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 33.53% upside from the last price of $61.41.

Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in Pacira BioSciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
7 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

11/25/2020

0 strong buy ratings
7 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

2/23/2021

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

5/24/2021

0 strong buy ratings
8 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

8/22/2021

0 strong buy ratings
8 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

11/20/2021

0 strong buy ratings
6 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

2/18/2022

0 strong buy ratings
5 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/19/2022

0 strong buy ratings
5 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

5/19/2022

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/1/2022	Northland Securities	Boost Price Target		$61.00 ➝ $67.00	High
2/26/2022	Wedbush	Reiterated Rating	Buy	$97.00 ➝ $94.00	Medium
2/25/2022	HC Wainwright	Boost Price Target	Buy	$86.00 ➝ $90.00	High
2/16/2022	Wedbush	Reiterated Rating	Buy	$97.00	Low
1/19/2022	Barclays	Boost Price Target	Overweight	$92.00 ➝ $96.00	Low
1/7/2022	Wedbush	Reiterated Rating	Buy	$97.00	High
1/4/2022	Northland Securities	Boost Price Target		$57.00 ➝ $61.00	Medium
1/3/2022	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$83.00	Medium
11/5/2021	Barclays	Boost Price Target	Overweight	$91.00 ➝ $92.00	High
11/4/2021	HC Wainwright	Boost Price Target	Buy	$80.00 ➝ $86.00	Low
10/18/2021	Needham & Company LLC	Boost Price Target	Buy	$80.00 ➝ $84.00	Low
10/12/2021	HC Wainwright	Lower Price Target	Buy	$84.00 ➝ $80.00	Medium
10/12/2021	BMO Capital Markets	Lower Price Target	Market Perform	$66.00 ➝ $60.00	Medium
10/5/2021	Northland Securities	Lower Price Target	Market Perform	$66.00 ➝ $57.00	High
10/1/2021	Barclays	Lower Price Target	Overweight	$95.00 ➝ $91.00	High
9/22/2021	Wedbush	Reiterated Rating	Buy	$93.00	Low
8/4/2021	HC Wainwright	Lower Price Target	Buy	$86.00 ➝ $84.00	Medium
7/26/2021	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$70.00 ➝ $75.00	Low
7/14/2021	HC Wainwright	Reiterated Rating	Buy	$86.00	Low
5/10/2021	BMO Capital Markets	Lower Price Target	Market Perform	$72.00 ➝ $70.00	Medium
5/5/2021	Northland Securities	Lower Price Target	Market Perform	$75.00 ➝ $66.00	Low
4/9/2021	Berenberg Bank	Initiated Coverage	Buy	$93.00	Low
3/1/2021	HC Wainwright	Boost Price Target	Buy	$70.00 ➝ $86.00	Low
2/26/2021	Barclays	Boost Price Target	Overweight	$79.00 ➝ $94.00	Medium
2/11/2021	Northland Securities	Downgrade	Outperform ➝ Market Perform	$72.00 ➝ $75.00	Low
1/25/2021	Northland Securities	Boost Price Target	Outperform	$67.00 ➝ $72.00	Medium
1/21/2021	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$63.00 ➝ $75.00	High
1/20/2021	Piper Sandler	Boost Price Target	Overweight	$65.00 ➝ $90.00	Low
1/8/2021	Needham & Company LLC	Boost Price Target	Buy	$67.00 ➝ $76.00	High
1/6/2021	Royal Bank of Canada	Boost Price Target	Outperform	$65.00 ➝ $70.00	N/A
12/14/2020	Barclays	Boost Price Target	Overweight	$73.00 ➝ $79.00	Low
12/9/2020	Needham & Company LLC	Lower Price Target	Buy	$68.00 ➝ $67.00	High
11/2/2020	Wedbush	Lower Price Target	Outperform	$85.00 ➝ $83.00	Low
10/7/2020	Wedbush	Reiterated Rating	Buy	$85.00	Medium
9/30/2020	Jefferies Financial Group	Boost Price Target		$69.00 ➝ $75.00	Low
9/21/2020	Northland Securities	Upgrade	Market Perform ➝ Outperform	$58.00 ➝ $67.00	Medium
9/9/2020	Needham & Company LLC	Boost Price Target	Buy	$64.00 ➝ $68.00	High
8/17/2020	Wedbush	Reiterated Rating	Buy	$85.00	Medium
8/14/2020	Truist Financial	Boost Price Target		$54.00 ➝ $65.00	Low
8/10/2020	HC Wainwright	Boost Price Target	Buy	$68.00 ➝ $70.00	High
7/20/2020	Wedbush	Reiterated Rating	Buy	$85.00	Low
7/13/2020	HC Wainwright	Reiterated Rating	Buy	$63.00 ➝ $68.00	High
7/10/2020	Jefferies Financial Group	Boost Price Target	Buy	$53.00 ➝ $69.00	Low
7/6/2020	Needham & Company LLC	Boost Price Target	Buy	$52.00 ➝ $64.00	Medium
7/6/2020	Piper Sandler	Boost Price Target	Positive ➝ Overweight	$49.00 ➝ $65.00	Medium
7/2/2020	Wedbush	Reiterated Rating	Buy	$85.00	N/A
7/1/2020	Royal Bank of Canada	Boost Price Target	Outperform	$56.00 ➝ $62.00	High
6/30/2020	SVB Leerink	Boost Price Target	Outperform	$45.00 ➝ $58.00	Medium
6/30/2020	Northland Securities	Boost Price Target	Market Perform	$50.00 ➝ $54.00	Low
5/27/2020	Northland Securities	Downgrade	Outperform ➝ Market Perform		Low
5/26/2020	Guggenheim	Initiated Coverage	Neutral		Low
5/13/2020	Royal Bank of Canada	Reiterated Rating	Buy	$56.00	High
5/12/2020	Wedbush	Reiterated Rating	Buy	$85.00	High
5/8/2020	SVB Leerink	Boost Price Target	Buy	$44.00 ➝ $45.00	Medium
5/7/2020	Stifel Nicolaus	Lower Price Target	Hold	$49.00 ➝ $48.00	Low
4/30/2020	Needham & Company LLC	Lower Price Target	Buy	$56.00 ➝ $52.00	High
4/27/2020	Wedbush	Reiterated Rating	Buy	$85.00	Medium
4/17/2020	Northland Securities	Reiterated Rating	Buy	$50.00	High
4/7/2020	Northland Securities	Initiated Coverage	Outperform	$50.00	High
3/23/2020	Piper Sandler	Lower Price Target		$60.00 ➝ $49.00	High
3/23/2020	Royal Bank of Canada	Lower Price Target	Outperform	$65.00 ➝ $56.00	High
3/20/2020	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$46.00 ➝ $44.00	High
2/24/2020	HC Wainwright	Boost Price Target	Buy	$60.00 ➝ $63.00	Medium
2/20/2020	Wedbush	Reiterated Rating	Buy	$85.00	N/A
2/20/2020	Stifel Nicolaus	Reiterated Rating	Hold	$49.00	High
2/20/2020	Piper Sandler	Boost Price Target	Buy	$54.00 ➝ $60.00	Low
1/23/2020	SunTrust Banks	Initiated Coverage	Buy	$60.00	Low
1/7/2020	Wedbush	Reiterated Rating	Buy	$85.00	Low
12/18/2019	Royal Bank of Canada	Reiterated Rating	Buy		Low
12/17/2019	Wedbush	Reiterated Rating	Buy	$85.00	Medium
11/8/2019	Barclays	Boost Price Target	Overweight	$52.00 ➝ $55.00	Medium
11/7/2019	Needham & Company LLC	Reiterated Rating	Buy	$56.00	High
11/7/2019	Cowen	Reiterated Rating	Hold	$41.00	High
11/6/2019	BTIG Research	Initiated Coverage	Buy	$56.00 ➝ $56.00	Medium
10/8/2019	Jefferies Financial Group	Set Price Target	Buy	$60.00	Low
8/9/2019	Stifel Nicolaus	Set Price Target	Hold	$42.00	Low
8/9/2019	BMO Capital Markets	Lower Price Target	Market Perform	$46.00 ➝ $43.00	Low
6/28/2019	Wedbush	Set Price Target	Buy	$85.00	Medium
6/12/2019	Wedbush	Reiterated Rating	Outperform	$85.00	Low
6/11/2019	Barclays	Initiated Coverage	Overweight ➝ Overweight	$52.00	Low
5/6/2019	Mizuho	Upgrade	Underperform ➝ Neutral	$29.00 ➝ $38.00	Low
5/3/2019	BMO Capital Markets	Set Price Target	Hold	$46.00	Low
5/2/2019	Stifel Nicolaus	Upgrade	Sell ➝ Hold	$45.00	Low
4/9/2019	Piper Jaffray Companies	Set Price Target	Buy	$55.00	Low
3/8/2019	Wedbush	Reiterated Rating	Outperform	$85.00	Low
3/8/2019	Stifel Nicolaus	Reiterated Rating	Positive ➝ Sell	$33.00	Low
3/1/2019	BMO Capital Markets	Set Price Target	Hold	$44.00	Medium
3/1/2019	Cowen	Reiterated Rating	Hold		Low
2/12/2019	National Securities	Initiated Coverage	Sell		Medium
2/1/2019	Mizuho	Downgrade	Neutral ➝ Underperform		High
1/29/2019	Wedbush	Set Price Target	Buy	$91.00	High
11/5/2018	Wedbush	Set Price Target	Buy	$85.00 ➝ $90.00	Low
11/5/2018	Mizuho	Boost Price Target	Neutral	$46.00	Medium
11/2/2018	JPMorgan Chase & Co.	Boost Price Target	Neutral ➝ Neutral	$45.00 ➝ $50.00	Low
11/2/2018	Jefferies Financial Group	Boost Price Target	Buy	$60.00	Low
11/2/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ Market Perform	$40.00 ➝ $47.00	Low
11/2/2018	Royal Bank of Canada	Set Price Target	Buy	$60.00	High
11/2/2018	HC Wainwright	Boost Price Target	Buy	$60.00	High
11/1/2018	JMP Securities	Boost Price Target	Market Outperform ➝ Buy	$56.00 ➝ $63.00	High
11/1/2018	Needham & Company LLC	Set Price Target	Buy	$60.00	High
11/1/2018	Piper Jaffray Companies	Set Price Target	Buy	$55.00	High
11/1/2018	Mizuho	Reiterated Rating	Hold	$43.00	High
10/10/2018	Bank of America	Boost Price Target	Neutral ➝ Neutral	$46.00 ➝ $48.00	High
10/9/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$51.00	High
9/19/2018	Royal Bank of Canada	Set Price Target	Buy	$55.00	High
9/13/2018	Stifel Nicolaus	Initiated Coverage	Sell	$41.00	Low
8/6/2018	Barclays	Boost Price Target	Overweight ➝ Buy	$40.00 ➝ $50.00	Low
8/6/2018	Wedbush	Reiterated Rating	Outperform	$85.00 ➝ $80.00	Low
8/6/2018	Wedbush	Set Price Target	Outperform ➝ Outperform	$85.00	Low
8/6/2018	Bank of America	Downgrade	Buy ➝ Neutral		Low
8/3/2018	Needham & Company LLC	Upgrade	Hold ➝ Buy	$54.00	High
8/3/2018	HC Wainwright	Reiterated Rating	Buy	$52.00	High
8/2/2018	Piper Jaffray Companies	Set Price Target	Buy	$48.00	High
8/2/2018	Royal Bank of Canada	Set Price Target	Buy	$50.00	High
8/2/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ Neutral	$40.00	High
7/26/2018	HC Wainwright	Set Price Target	Buy	$48.00	High
7/10/2018	Cowen	Reiterated Rating	Hold		Medium
7/10/2018	HC Wainwright	Reiterated Rating	Buy	$48.00	Medium
6/29/2018	Mizuho	Reiterated Rating	Hold	$31.00	Low
5/17/2018	Oppenheimer	Reiterated Rating	Hold		Low
5/4/2018	JMP Securities	Set Price Target	Outperform ➝ Buy	$65.00 ➝ $56.00	Medium
5/3/2018	Mizuho	Reiterated Rating	Hold	$31.00	Medium
5/3/2018	HC Wainwright	Set Price Target	Buy	$48.00	Low
4/30/2018	Wedbush	Reiterated Rating	Outperform	$80.00	Medium
4/10/2018	JPMorgan Chase & Co.	Boost Price Target	Neutral ➝ Neutral	$40.00 ➝ $43.00	Low
4/9/2018	Wedbush	Lower Price Target	Outperform	$72.00 ➝ $80.00	High
4/9/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ Market Perform	$31.00 ➝ $34.00	Low
4/9/2018	JPMorgan Chase & Co.	Reiterated Rating	Neutral ➝ Hold	$40.00 ➝ $43.00	Low
4/9/2018	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $48.00	Medium
4/9/2018	Piper Jaffray Companies	Set Price Target	Buy	$44.00	Medium
3/21/2018	Mizuho	Lower Price Target	Neutral ➝ Neutral	$44.00 ➝ $31.00	High
3/1/2018	BMO Capital Markets	Lower Price Target	Market Perform ➝ Market Perform	$32.00 ➝ $31.00	Medium
3/1/2018	Royal Bank of Canada	Set Price Target	Buy	$44.00	High
3/1/2018	HC Wainwright	Set Price Target	Buy	$45.00	High
3/1/2018	Oppenheimer	Reiterated Rating	Hold		High
2/16/2018	Needham & Company LLC	Downgrade	Buy ➝ Hold	$55.00	High
2/16/2018	Barclays	Reiterated Rating	Buy	$40.00	High
2/15/2018	BMO Capital Markets	Lower Price Target	Market Perform	$41.00 ➝ $32.00	High
2/15/2018	Oppenheimer	Reiterated Rating	Hold		High
2/13/2018	Piper Jaffray Companies	Set Price Target	Buy	$49.00	Low
1/5/2018	Wedbush	Reiterated Rating	Buy		Low
1/4/2018	HC Wainwright	Set Price Target	Buy ➝ Buy	$52.00 ➝ $55.00	Low
1/4/2018	JPMorgan Chase & Co.	Reiterated Rating	Hold		Low
1/4/2018	Royal Bank of Canada	Set Price Target	Buy	$54.00	High
1/2/2018	SVB Leerink	Initiated Coverage	Mkt Perform ➝ Market Perform	$46.00	Low
12/20/2017	Wedbush	Reiterated Rating	Buy	$80.00	Low
12/18/2017	JPMorgan Chase & Co.	Initiated Coverage	Neutral ➝ Neutral	$47.00	High
11/29/2017	Mizuho	Downgrade	Buy ➝ Neutral	$53.00 ➝ $44.00	Medium
11/20/2017	Wedbush	Reiterated Rating	Buy	$80.00	N/A
11/16/2017	Janney Montgomery Scott	Set Price Target	Sell	$27.00	N/A
11/9/2017	Oppenheimer	Reiterated Rating	Hold		N/A
11/9/2017	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$52.00	N/A
11/9/2017	Jefferies Financial Group	Lower Price Target	Buy	$52.00	N/A
11/8/2017	BMO Capital Markets	Boost Price Target	Market Perform	$38.00 ➝ $39.00	N/A
10/27/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$55.00	N/A
10/26/2017	Janney Montgomery Scott	Downgrade	Neutral ➝ Sell	$27.00	N/A
10/25/2017	Wedbush	Reiterated Rating	Outperform	$87.00	N/A
10/19/2017	Needham & Company LLC	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $52.00	N/A
10/13/2017	Royal Bank of Canada	Reiterated Rating	Buy	$54.00	N/A
10/4/2017	Bank of America	Lower Price Target	Buy	$46.00 ➝ $45.00	Low
9/28/2017	The Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$41.00	Medium
9/26/2017	Needham & Company LLC	Reiterated Rating	Buy		Low
9/25/2017	Mizuho	Reiterated Rating	Buy	$53.00	Medium
9/7/2017	Jefferies Financial Group	Reiterated Rating	Buy	$59.00	Medium
9/7/2017	CIBC	Initiated Coverage	Market Perform ➝ Market Perform		Low
9/7/2017	Oppenheimer	Initiated Coverage	Market Perform		Medium
9/6/2017	UBS Group	Initiated Coverage	Market Perform		Medium
9/5/2017	Royal Bank of Canada	Reiterated Rating	Outperform	$54.00	Medium
8/23/2017	Wedbush	Reiterated Rating	Outperform	$87.00	Medium
8/22/2017	Mizuho	Reiterated Rating	Buy	$54.00 ➝ $53.00	Low
8/22/2017	Needham & Company LLC	Initiated Coverage	Buy ➝ Buy	$55.00	Low
8/21/2017	Janney Montgomery Scott	Upgrade	Sell ➝ Neutral	$31.00	Low
8/3/2017	BMO Capital Markets	Lower Price Target	Market Perform	$42.00 ➝ $40.00	Low
8/3/2017	HC Wainwright	Set Price Target	Buy	$59.00	Medium
8/2/2017	Cowen	Reiterated Rating	Hold		Medium
7/30/2017	Royal Bank of Canada	Set Price Target	Buy	$58.00	Low
7/26/2017	Mizuho	Reiterated Rating	Buy	$54.00	Medium
7/19/2017	Wedbush	Reiterated Rating	Outperform	$87.00	Low
7/14/2017	Cowen	Reiterated Rating	Hold		Low
6/27/2017	Royal Bank of Canada	Set Price Target	Buy	$58.00	N/A
6/21/2017	Wedbush	Reiterated Rating	Outperform	$87.00	High
5/24/2017	Wedbush	Reiterated Rating	Outperform	$87.00	Low

(Data available from 5/19/2017 forward)

News Sentiment Rating

0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

7 very positive mentions
9 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

10/21/2021

2 very positive mentions
11 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

11/20/2021

1 very positive mentions
4 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

12/20/2021

1 very positive mentions
2 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

1/19/2022

4 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/18/2022

2 very positive mentions
7 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/20/2022

0 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/19/2022

2 very positive mentions
9 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

5/19/2022

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Today's Range

Now: $61.41

$60.67

$63.66

50 Day Range

MA: $72.18

$59.51

$81.64

52 Week Range

Now: $61.41

$45.05

$82.16

Volume

406,147 shs

Average Volume

543,599 shs

Market Capitalization

$2.79 billion

P/E Ratio

73.11

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Pacira BioSciences?: The following Wall Street sell-side analysts have issued research reports on Pacira BioSciences in the last twelve months: Barclays PLC, BMO Capital Markets, HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, Northland Securities, StockNews.com, TheStreet, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for PCRX.
What is the current price target for Pacira BioSciences?: 0 Wall Street analysts have set twelve-month price targets for Pacira BioSciences in the last year. Their average twelve-month price target is $82.00, suggesting a possible upside of 33.5%.
View the latest price targets for PCRX.
What is the current consensus analyst rating for Pacira BioSciences?: Pacira BioSciences currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PCRX will outperform the market and that investors should add to their positions of Pacira BioSciences.
View the latest ratings for PCRX.
What other companies compete with Pacira BioSciences?: Other companies that are similar to Pacira BioSciences include Johnson & Johnson, Pfizer, Eli Lilly and, AbbVie, Merck & Co., Inc., Bristol-Myers Squibb, Zoetis, Royalty Pharma, Horizon Therapeutics Public, Jazz Pharmaceuticals, Perrigo, Corcept Therapeutics, Supernus Pharmaceuticals, Nektar Therapeutics and Omeros. Learn More about companies similar to Pacira BioSciences.
How do I contact Pacira BioSciences' investor relations team?: Pacira BioSciences' physical mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company's listed phone number is (813) 553-6680 and its investor relations email address is [email protected] The official website for Pacira BioSciences is www.pacira.com. Learn More about contacing Pacira BioSciences investor relations.

NASDAQ:PCRX - Pacira BioSciences Stock Price Target and Predictions

Analyst Price Target for PCRX

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.15 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Pacira BioSciences?

What is the current price target for Pacira BioSciences?

What is the current consensus analyst rating for Pacira BioSciences?

What other companies compete with Pacira BioSciences?

How do I contact Pacira BioSciences' investor relations team?